DirectX

First patch of "Operation Medic Bag" out now with first improvements and features : Starbreeze AB

Retrieved on: 
Friday, March 1, 2024

STOCKHOLM, March 1, 2024 /PRNewswire/ -- "Operation Medic Bag" is a focused effort to respond to community expectations and improve PAYDAY 3.

Key Points: 
  • STOCKHOLM, March 1, 2024 /PRNewswire/ -- "Operation Medic Bag" is a focused effort to respond to community expectations and improve PAYDAY 3.
  • The initiative covers a range of sought-after features and improvements to gameplay, stability, matchmaking, content and enhanced features.
  • The first patch of "Operation Medic Bag" includes focus initiatives such as rotating stealth modifiers, unready button and improved controller settings.
  • Updates under the "Operation Medic Bag" umbrella are scheduled to increase in cadence, releasing smaller updates more frequently over time.

Acer Expands Gaming Portfolio with New Predator BiFrost and Nitro Series Graphics Cards

Retrieved on: 
Monday, January 8, 2024

LAS VEGAS, Jan. 8, 2024 /PRNewswire/ -- Acer today announced the Predator BiFrost AMD Radeon™ RX 7800 XT OC and a trio of Nitro graphic cards powered by the latest AMD Radeon RX 7000 series GPUs, including the new AMD Radeon RX 7600 XT GPUs. The new graphics cards empower users to experience immersive gaming experiences when playing the latest AAA titles with up to 16GB memory and next-gen technologies.

Key Points: 
  • Acer's latest desktop graphics cards push the boundaries of gaming and creative workflows.
  • The Predator BiFrost AMD Radeon RX 7800 XT OC graphics card fuses the prowess of the AMD RDNA 3 chiplet design and Acer's latest technology advancements.
  • The Acer Nitro AMD Radeon RX 7800 XT OC and Nitro AMD Radeon RX 7700 XT OC graphics cards are primed to present the latest games in their full visual splendor.
  • The Acer Nitro AMD Radeon RX 7600 XT OC graphics card incorporates cutting-edge features for reliable performance.

Imagination Launches Brand New Line of High-performance GPU IP with DirectX

Retrieved on: 
Tuesday, November 7, 2023

Imagination Technologies launches IMG DXD, the first product in a new line of high-performance GPU IP with support for DirectX®*.

Key Points: 
  • Imagination Technologies launches IMG DXD, the first product in a new line of high-performance GPU IP with support for DirectX®*.
  • Products based on Imagination IP are used by billions of people across the globe in their smartphones, cars, homes, and workplaces.
  • Imagination, PowerVR, and the Imagination Technologies logo are trademarks of Imagination Technologies Limited and/or its affiliated group companies in the United Kingdom and/or other countries.
  • *IMG DXD is a GPU IP based on the published DirectX and Khronos API specifications.

CodeWeavers Announces Release of CrossOver 23.5

Retrieved on: 
Wednesday, September 27, 2023

CodeWeavers , the software development company behind CrossOver, today announced its release of CrossOver 23.5 for macOS, Linux, and ChromeOS.

Key Points: 
  • CodeWeavers , the software development company behind CrossOver, today announced its release of CrossOver 23.5 for macOS, Linux, and ChromeOS.
  • CrossOver 23.5 offers Mac gamers significantly improved and simplified gameplay access to the most Windows games on Mac in CodeWeavers’ company history!
  • This release offers an alternate way to run DirectX 11 and DirectX 12 games through CrossOver using its toolkit components.
  • CrossOver 23.5 is the first CrossOver release with support for macOS Sonoma with optimizations from thorough compatibility testing.

First HP Work Relationship Index Shows Majority of People Worldwide Have an Unhealthy Relationship with Work

Retrieved on: 
Wednesday, September 20, 2023

PALO ALTO, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today unveiled groundbreaking findings from its first HP Work Relationship Index, a comprehensive study that explores employees’ relationships with work around the world.* The study, which surveyed more than 15,600 respondents across various industries in 12 countries, reveals the world’s relationship with work is at a breaking point – and its effects are pervasive.

Key Points: 
  • Through this, HP developed its Work Relationship Index, which is a measure of the world’s relationship with work to be tracked over time.
  • The findings spotlight the negative impacts an unhealthy relationship with work has on an employee’s life and an employer’s business.
  • The Work Relationship Index shows that this is a pivotal time to redefine the world’s relationships with work.
  • For more information on the Work Relationship Index, please visit the WRI Website and to access the full report, please visit the HP Newsroom .

Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

Retrieved on: 
Tuesday, July 25, 2023

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer , addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer , addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion.
  • Early system evaluations and conversations with users suggest that the DxI 9000 Analyzer opens up new opportunities to quantify trace amounts of key biomarkers in blood samples.
  • Initial assay development efforts will focus on the recently introduced DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers.
  • The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics

Retrieved on: 
Monday, July 17, 2023

The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer’s Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • To complement the current diagnostic solutions, which rely on PET-imaging or a lumbar puncture for cerebral spinal fluid testing, Fujirebio and Beckman Coulter intend to bolster widespread access to patient-friendly, blood-based diagnostic capabilities which will complement and accelerate the impact of breakthrough Alzheimer’s Disease therapeutics.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer’s Disease care.”
    “This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test

Retrieved on: 
Monday, July 17, 2023

BREA, Calif. and TOKYO, July 17, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving Alzheimer's patients' health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer's Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer's Disease care."
  • The availability of these new biomarkers allows clinical research professionals to further investigate clinical utility in assessing Alzheimer's Disease or other neurological disease conditions.

Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

Retrieved on: 
Monday, May 15, 2023

ROME, May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).  

Key Points: 
  • According to Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics, "The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow's analytical needs.
  • In particular, the team loved the un-paralleled Zero Daily Maintenance especially for a platform that runs 450 tests per hour."
  • Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.
  • Speakers include Dr. Pamela Christudoss, and Kathleen Orland, Senior Vice President & General Manager, Clinical Chemistry and Immunoassay Business Unit, Beckman Coulter Diagnostics.

Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

Retrieved on: 
Monday, May 15, 2023

ROME, May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).  

Key Points: 
  • According to Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics, "The DxI 9000 Access Immunoassay Analyzer sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow's analytical needs.
  • In particular, the team loved the un-paralleled Zero Daily Maintenance especially for a platform that runs 450 tests per hour."
  • Beta users attest to ZeroDaily Maintenance redefining their workday with no daily maintenance requirements, thereby reducing annual maintenance routines by up to 96%.
  • Speakers include Dr. Pamela Christudoss, and Kathleen Orland, Senior Vice President & General Manager, Clinical Chemistry and Immunoassay Business Unit, Beckman Coulter Diagnostics.